Key Highlights
- Corbus Pharmaceuticals announced favorable Phase 1b CANYON-1 trial results for once-daily oral CRB-913 in obesity.
- The trial showed statistically significant weight reduction across all cohort dosages.
- The 60 mg arm showed a 5.0% average decrease at 12 weeks with no observed plateau.
- The safety profile was tolerable, with no suicidal Ideation signals observed.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced favorable Phase 1b CANYON-1 trial results evaluating once-daily oral CRB-913 for obesity, demonstrating statistically significant weight reduction across all cohort dosages.
What Happened
The results were highlighted by a 5.0% average decrease in the 60 mg arm at 12 weeks with no observed plateau, alongside a tolerable safety profile devoid of suicidal ideation signals, paving the way for regulatory interactions and a Phase 2 monotherapy trial commencement targeted for the first half of 2027.
Market Reaction
The disclosed information does not include stock price or trading data for Corbus Pharmaceuticals following the CANYON-1 results.
Outlook
Planned regulatory interactions and the targeted Phase 2 monotherapy trial start in the first half of 2027 represent the next major disclosed milestones for CRB-913 in obesity.
FAQs
Q: What did Corbus Pharmaceuticals' CANYON-1 trial show?
A: Statistically significant weight reduction across all cohort dosages of oral CRB-913, with a 5.0% average decrease in the 60 mg arm at 12 weeks and no observed plateau.
Q: Were there safety concerns with CRB-913?
A: No, the safety profile was tolerable and devoid of suicidal ideation signals.
Q: What is the next step for CRB-913?
A: Regulatory interactions and a Phase 2 monotherapy trial targeted to begin in the first half of 2027.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.